April 15, 2016
The risk of dyslipidemia increases by about three times in patients receiving the atypical antipsychotic (AAP) olanzapine compared to when they are not taking the drug, a pharmacoepidemiology study by the Pharmaceuticals and Medical Devices Agency (PMDA) showed. The PMDA...read more